InProTher, a Copenhagen, Denmark-based early-stage biotechnology company developing effective immunotherapies targeting the Human Endogenous Retroviruses (HERVs), raised EUR 6M Seed funding.
Backers included private investors and the European Innovation Council (EIC) Fund.
The company intends to use the funds to advance its lead drug candidate, IPT001, a first-in-class immunotherapy against solid tumors, into clinical development.
Incubated at the BioInnovation Institute (BII) and seeded by the Novo Nordisk Foundation, InProTher was established to develop immunotherapies designed to overcome the limitations of cancer vaccines.
Led by Jordi Naval, Chief Executive Officer, the company is targeting the Human Endogenous Retroviruses (HERVs) to treat cancer. HERVS are well recognized as tumor specific antigens, but until now, have been undruggable. InProTher is targeting HERV tumor antigens with powerful technology that stimulates both arms of the immune system, the humoral and the cellular response. The company delivers the immunogen by using Adenoviral and RNA vectors.
InProTher has generated pre-clinical, proof-of-concept data that demonstrates therapeutic potential for multiple oncology indications including pancreatic, ovarian, breast and prostate cancer. It plans to enter First-In-Human (FIH) trials in 2024.
To support its growth, InProTher has appointed Dr Hamina Patel, MD, as Chief Medical Officer, and Dr Sven Rohmann, MD, PhD, MBA as Chairman of the Board of Directors.
FinSMEs
24/05/2023